


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Idaho Falls Community Hospital, LLC</p> <p>2. 2327 Coronado Street Idaho Falls, ID 83404</p>		<p>In accordance with letter dated June 20, 2022,</p>	<p>4. Expiration Date: October 31, 2034</p>
		<p>3. License No.: 11-35569-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-39202 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine-131 permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Capsules</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 400 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-35569-01

Docket or Reference No.:
030-39202

Amendment No. 2

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 2327 Coronado Street, Idaho Falls, Idaho, 83404.

11. The Radiation Safety Officer (RSO) for this license is David J. Theel, M.S.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
Richard W. Bently, M.D.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
Michael C. Biddulph, M.D.	35.100; 35.200; 35.300
Dirk E. Bigler, D.O.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
Douglas U. Blank, M.D.	35.200
Michael T. Callaghan, M.D.	35.200; 35.300
John D. Chambers, Jr., M.D.	35.200
Christopher O. Harker, M.D.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
James B. Harris, M.D.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
Justin A. Lamb, D.O.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Daniel S. Madsen, M.D.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
Calvin J. McAllister, M.D.	35.200; 35.300
Stephen R. Preece, M.D.	35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
James F. Schmutz, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-35569-01

Docket or Reference No.:
030-39202

Amendment No. 2

Authorized User (M.D., D.O., etc.)

Steven D. Smith, M.D.

John J. Strobel, M.D.

Steven J. Todd, M.D.

David R. Warden III, M.D.


Material and Use

35.100; 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131

35.100; 35.200; 35.300

35.100; 35.200; 35.300

35.100; 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-35569-01

Docket or Reference No.:
030-39202

Amendment No. 2

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated August 20, 2019 (ML19281D846)
- B. Item 4 of email dated October 14, 2019 and application dated August 20, 2019 - change page only containing revised occupational dose commitment (ML19289B965)
- C. Letter dated October 25, 2019 with enclosures (ML19303C935)
- D. Letter dated March 19, 2021 (ML21081A280)
- E. E-mail dated June 15, 2021 with attachments (ML21168A047)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 7, 2022

By: _____

Michelle R. Simmons
Region 4